BPC-157 + TB-500 dosage and protocol
BPC-157 + TB-500 dosage has no study of its own: no published trial has tested this blend. This page splits each dose into its parts (BPC-157, TB-500) and shows what is known about each one.
What BPC-157 + TB-500 dosage is on record?
10 mg vial: 5 mg BPC-157 + 5 mg TB-500No study of this blend as a blend was found. Everything known is about its parts.
Checked 10 Oct 2026 against labels, PubMed and the US and Canadian regulators.
What is in BPC-157 + TB-500
Peptides Power sells BPC-157 + TB-500 as one 10 mg vial. Every draw from it carries the parts in the same ratio, shown below.
BPC-157 in BPC-157 + TB-500
BPC-157 is a synthetic peptide of 15 amino acids (a pentadecapeptide) that was originally isolated from gastric juice. No approved medicine containing it was found in the US or Canada. (1)
- Small human studyA 2025 review counted only three pilot studies of BPC-157 in humans: knee pain, interstitial cystitis and intravenous safety. (1)
- ObservationalIn a retrospective chart review with phone follow-up, 11 of 12 patients given BPC 157 alone into the knee joint reported significant improvement in knee pain. The abstract gives no dose and says no specific tools were used to measure function. (2)
- ObservationalFour more patients in the same chart review were given BPC 157 together with thymosin beta-4 (written TB4) into the knee. This is the only human report of the two given together that was found. (2)
- ObservationalOf those four, 75% reported significant improvement and 25% had no relief. (2)
- ObservationalA systematic review of the literature to June 2024 found 35 preclinical studies and 1 clinical study. (3)
- ObservationalThat review describes the knee series differently from its own abstract: 7 of 12 patients with relief lasting more than 6 months. (3)
Human doses on record for BPC-157 alone: 10 mg in 250 mL of normal saline (one infusion on day 1); 20 mg in 250 mL of normal saline (one infusion on day 2); 10 mg in total (single procedure) (4, 5).
US status: Not FDA approved. FDA lists BPC-157 among bulk substances that were in compounding category 2 until the nominations were withdrawn; it is in none of the three categories on the 14 May 2026 list. (6)
TB-500 in BPC-157 + TB-500
TB-500 is a product name. The peptide identified in it is Ac-LKKTETQ, the acetylated fragment made of amino acids 17 to 23 of thymosin beta-4. It is a 7-amino-acid piece, not the full 43-amino-acid thymosin beta-4 that was used in the human trials. (7)
- Lab studyLaboratory analysis of a TB-500 product identified its peptide as Ac-LKKTETQ, the N-terminal acetylated 17-23 fragment of human thymosin beta-4. (7)
- Lab studyAn equine doping-control study described TB-500 in 2012 as a veterinary preparation whose key ingredient is LKKTETQ with an acetyl group added to the N-terminus. (8)
- Animal studyIn that doping-control study, horses were given a single dose of TB-500 containing 10 mg of the peptide so that it could be detected in urine and plasma. It was not a study of benefit. (8)
- Lab studyA 2024 metabolism study states that the biological effects of TB-500 itself have not been documented. (9)
- Lab studyIn that study, only one breakdown product (Ac-LKKTE) showed significant wound-healing activity in fibroblast cell tests; the authors suggest activity credited to TB-500 may come from this metabolite. (9)
- Lab studyAnalysis of TB500 and TB1000 products sold online found that what they contain does not consistently match how they had been described. (10)
TB-500 alone has no published human dose on record.
US status: Not FDA approved. FDA lists the thymosin beta-4 fragment LKKTETQ, also known as TB-500, among bulk substances that were in compounding category 2 until the nominations were withdrawn, and says it has found no human exposure data for it. (11)
How to reconstitute BPC-157 + TB-500
BPC-157 + TB-500 comes as a dry powder (10 mg vials). Reconstituting it means adding bacteriostatic water so it can be drawn into a syringe. The water does not change how much BPC-157 + TB-500 is in the vial, only how strong each mL is, so it decides how many syringe units a dose takes.
| Vial | Water | Strength | What 10 units holds | Doses between 5 and 100 units |
|---|---|---|---|---|
| 10 mg | 1 mL | 10 mg/mL | 1 mg in every 10 units | 500 mcg to 10 mg |
| 10 mg | 2 mL | 5 mg/mL | 500 mcg in every 10 units | 250 mcg to 5 mg |
| 10 mg | 3 mL | 3.333 mg/mL | 333 mcg in every 10 units | 167 mcg to 3.33 mg |
The last column is the range of doses that land between the 5 unit mark (small marks are hard to read) and the 100 unit mark of a 1 mL U-100 syringe for that mix. All of it is arithmetic.
Reconstitution steps
- Wash your hands, work in a clean area and set out the BPC-157 + TB-500 vial, bacteriostatic water, a sterile syringe, alcohol pads and a sharps container (13).
- Check the vial and the water: right product, in date, intact cap (13).
- Wipe both rubber tops with an alcohol pad and let them dry (13).
- Draw the water amount you picked from the table into the syringe.
- Push the needle through the BPC-157 + TB-500 vial stopper and let the water in slowly.
- Move the vial in a circle until the powder is fully dissolved. Do not shake it (14).
- Check the liquid. MedlinePlus says not to use it if it has changed color, has floating pieces or is cloudy (13).
- Write the date you mixed it on the vial (13), and note the water amount so every later draw uses the same numbers.
After mixing
No published storage data exists for mixed BPC-157 + TB-500; the bacteriostatic water label says not to store a mixed drug unless its maker says you can (12).
For any other vial size, water amount or dose, use the BPC-157 + TB-500 reconstitution calculator.
Injecting under the skin
General steps for an injection under the skin, from MedlinePlus (15). Labels for approved products give their own instructions, which come first.
- Pick a site: the belly (below the ribs, above the hip bones and at least 2 inches from the belly button), the outer upper thigh, or the back or side of the upper arm.
- Move to a new spot each time, at least 1 inch from the last one. MedlinePlus says this keeps the skin healthy and helps the body absorb the medicine.
- Wash your hands with soap and running water for at least 1 minute, dry them, then clean the skin with an alcohol pad and let it dry.
- Pinch about an inch of skin and fat, put the needle in quickly at 90 degrees (45 degrees if there is little fat), let go of the skin and push the plunger all the way.
- Pull the needle out, put it straight into a sharps container, and press clean gauze on the spot for a few seconds. Never reuse a needle or syringe.
- Some soreness is expected. MedlinePlus says to contact a health care provider for signs of infection such as redness, swelling, red streaks or fever.
To draw the right amount, use the BPC-157 + TB-500 calculator and the drawing steps on that page.
BPC-157 + TB-500 dosage questions
What is the BPC-157 + TB-500 dosage?
No study has tested BPC-157 + TB-500 as a blend, so there is no tested BPC-157 + TB-500 dosage. One 10 mg vial holds 5 mg BPC-157, 5 mg TB-500, and every draw carries them in that ratio.
How many units of BPC-157 + TB-500 do I draw?
Use the BPC-157 + TB-500 calculator: pick your vial, water and dose, and it gives the units on a U-100 insulin syringe.
Sources
- McGuire FP et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med 2025. PubMed 40789979
- Lee E et al. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med 2021. PubMed 34324435
- Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025. PubMed 40756949
- Lee E et al. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med 2024. PubMed 39325560
- Lee E et al. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025. PubMed 40131143
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov
- Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal 2012. PubMed 22962027
- Ho EN et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A 2012. PubMed 23084823
- Rahaman KA et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci 2024. PubMed 38382158
- Delcourt V et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal 2023. PubMed 36482504
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov
- Bacteriostatic Water for Injection, USP (Hospira) label. DailyMed
- MedlinePlus, Drawing medicine out of a vial (reviewed 14 Jan 2026). medlineplus.gov
- Egrifta WR (tesamorelin) US prescribing information, section 2.2. DailyMed
- MedlinePlus, Subcutaneous (SQ) injections. medlineplus.gov
Facts checked 10 Oct 2026 against the sources above. This page reports what labels and published studies used. It is not medical advice: talk to a licensed prescriber before you start, stop or change anything.